Rapid identification of antiviral compounds and/or inhibitors that block SARS-CoV-2 infection:
Antiviral compounds (i.e., that can be used to treat virus infections) and/or compounds that prevent SARS-CoV2 infection will be identified.
Three parallel approaches will be adopted: (1) Immediate testing of composite libraries (more than 1,400); (2) Use of computer techniques to screen and evaluate the compounds; (3) Development of inhibitors (compounds that block SARS-CoV-2 infection).
The final evaluation of drug effectiveness and resistance results will be done with SARS-CoV-2.
Principal Investigators: M. Jesús Pérez (IQM), Sonsoles Martín (CIB)
